MedTrace Logo

Safety, Tolerability, PK of Oral NYX-2925 in Healthy Volunteers

NCT02834741 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 84

Last updated 2017-04-05

No results posted yet for this study

Summary

This is a first in human study of NYX-2925. It will evaluate single and multiple ascending doses of NYX-2925 in healthy volunteers.

Conditions

  • Healthy Volunteers

Interventions

DRUG

NYX-2925

NYX-2925 is a small molecule that acts as an N-methyl-D-aspartate receptor (NMDAR) functional glycine-site partial agonist.

Sponsors & Collaborators

  • Spaulding Clinical Research LLC

    collaborator OTHER

  • Aptinyx

    lead INDUSTRY

Principal Investigators

  • Carlos Sanabria, MD · Spaulding Clinical Research LLC

  • Laurel Sindelar · Aptinyx Inc.

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
55 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2016-07-31
Primary Completion
2017-03-31
Completion
2017-03-31

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02834741 on ClinicalTrials.gov